A phase I open-label multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

Brief description of study

This study is a FIH, open-label, phase I, multi-center study that consists of two treatment arms in dose escalation: single-agent KFA115 (Arm A escalation) and KFA115 in combination with pembrolizumab preceded by a KFA115 run-in for 1 cycle (Arm B escalation). In expansion, the study consists of three treatment arms: single-agent KFA115 (Arm A expansion), KFA115 in combination with pembrolizumab after single-agent KFA115 run-in (Arm B expansion), and KFA115 to be initiated with pembrolizumab concurrently (Arm C expansion).


Clinical Study Identifier: s23-01023
ClinicalTrials.gov Identifier: NCT05544929
Principal Investigator: Kristen Spencer.
Other Investigators: Nila Theresa De La Rosa, Scot Niglio, Nina Beri, Elise M Zahriah, Jessica Wang, Elaine Shum, Salman Rafi Punekar, Samantha VanMaanen, Ann M Riccobene, Joshua K Sabari, Keriann M Scavone, Zujun Li, Kathleen M Madden, Eneil De La Pena, Nancy Chan, Megan DiBenedetto, Douglas K Marks, Janice Mehnert, Ruth A White, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.